Generics - AstraZeneca, Asia-Pacific

Filter

Current filters:

AstraZenecaAsia-Pacific

Popular Filters

Further savings expected following Australian Crestor patent decision, says GMiA

07-03-2013

In a decision brought down by the Australian Federal Court earlier this week, suppliers of generic medicines…

Asia-PacificAstraZenecaCardio-vascularCrestorGenericsPatentsPharmaceuticalPricing

AstraZeneca drops early-stage obesity drug; Roche loses out on Indian Tarceva dispute

10-09-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has told its development partner Palatin Technologies…

Asia-PacificAstraZenecaCiplaErlocipGenericsMetabolicsOncologyPalatin TechnologiesPatentsPharmaceuticalResearchRocheTarceva

Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too

04-05-2012

Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used…

Asia-PacificAstraZenecaBayerCiplaGenericsIressaMerck & CoNexavarOncologyPharmaceuticalPricingTemodar

AstraZeneca expands in China, cuts back in USA

08-12-2011

It was a busy couple of days for Anglo-Swedish drug major AstraZeneca (LSE: AZN), with the company yesterday…

Asia-PacificAstraZenecaGenericsGuangdong BeiKang PharmaManagementMergers & AcquisitionsNorth AmericaPharmaceutical

Back to top